Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.42 |
| ▸ | CNR2 | P34972 | 3/20 | 0.42 |
| ▸ | MPL | P40238 | 1/20 | 0.42 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.37 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.37 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | ATR | Q13535 | 2/20 | 0.36 |
| ▸ | KMO | O15229 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19365710 | 0.90 | CNR2 (0.52) | GRM5CNR2MCHR1ALDH1A1ATR | |
| SCHEMBL19365852 | 0.88 | MPL (0.41) | GRM5CNR2MPLALDH1A1CHRNB2 | |
| SCHEMBL19670421 | 0.88 | MPL (0.44) | MPLMCHR1ALDH1A1CHRNB2CHRNB4 | |
| SCHEMBL19365606 | 0.87 | ATR (0.48) | CHRNB2CHRNB4CHRNA3CHRNA4ATR | |
| SCHEMBL19364806 | 0.87 | CNR2 (0.43) | GRM5CNR2MCHR1ATRMEN1 | |
| SCHEMBL19365569 | 0.87 | MCHR1 (0.41) | GRM5MCHR1ATR | |
| SCHEMBL19706193 | 0.85 | CNR2 (0.40) | GRM5CNR2MCHR1ALDH1A1ATR | |
| SCHEMBL19365311 | 0.84 | CNR2 (0.39) | GRM5CNR2MCHR1ATRMAP4K4 | |
| SCHEMBL19670413 | 0.83 | ATR (0.43) | ATR | |
| SCHEMBL19365310 | 0.83 | TSHR (0.45) | GRM5CNR2MCHR1ATRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | GRM5 3471/4885CNR2 2514/4885MPL 3547/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | GRM5 3471/4885CNR2 2514/4885MPL 3547/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.